• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Labetalol vs Nifedipine for Preeclampsia: How do they Affect Cerebral Perfusion Pressure?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Women with preeclampsia have elevated cerebral perfusion pressure
  • Tolcher et al. (AJOG, 2020) compared cerebral perfusion pressure before and after IV labetalol vs oral nifedipine during severe hypertension in pregnancy

METHODS:

  • Prospective cohort study
  • Participants
    • Between 24 and 42 weeks gestation | Severe hypertension
    • Exclusion criteria: Active labor |Received other antihypertensive medication within 2 hours of initial cerebral perfusion pressure measurement
  • Exposures
    • Labetalol group: 20 mg IV
    • Nifedipine group: 10 mg oral  
  • Study design
    • Severe hypertension: SBP ≥160 and/or DBP ≥110
    • Peripheral blood pressure and transcranial MCA Doppler studies obtained
      • Before medication administration
      • 30 minutes after medication administration
    • Cerebral perfusion pressure can be measured with non-invasive transcranial Doppler
  • Multiple baseline data were obtained, including
    • Maternal age | Parity | Race and ethnicity | BMI Gestational age | Pre-existing diabetes or hypertension | FGR | Magnesium sulfate
  • Primary outcome
    • Change in cerebral perfusion pressure

RESULTS:

  • 16 women were enrolled | 8 women in each group
    • No significant baseline characteristic differences between groups 
  • There was a significantly greater decrease in the following 30 minutes after the administration of oral nifedipine vs IV labetalol for the following
    • Systolic blood pressure (P = 0.003)
      • Intravenous labetalol: -9.8 mmHg
      • Oral nifedipine: -39 mmHg
    • Mean arterial pressure (P = 0.02)
      • Intravenous labetalol: -7.1 mmHg
      • Oral nifedipine: -22.3 mmHg
    • Cerebral perfusion pressure (P = 0.01)
      • Intravenous labetalol: -2.5 mmHg
      • Oral nifedipine: -27.7 mmHg
  • There was no statistically significant difference in
    • Diastolic pressure (P = 0.15)
      • Intravenous labetalol: -12.9 mmHg
      • Oral nifedipine: -5.4 mmHg
    • Change in middle cerebral artery velocity by transcranial Doppler (P = 0.64)
      • Intravenous labetalol: 0.07 cm/s
      • Oral nifedipine: 0.16 cm/s

CONCLUSION:

  • Cerebral perfusion pressure was significantly decreased following a single dose of oral nifedipine vs IV labetalol in patients with severe hypertension in the setting of preeclampsia
  • The evidence suggests that this decrease is not due to a change in cerebral blood flow but rather a decrease in peripheral arterial blood pressure
  • The authors note that future research should include Doppler measurements of anterior and especially posterior cerebral arteries as “most neuropathology in the setting of preeclampsia occurs in the occipital region”

Learn more – Primary Sources:

Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ACOG Guidance: Emergency Treatment for Severe Hypertension in Pregnancy
Labetalol or Nifedipine for Acute Elevated BP in Pregnancy?
Severe Hypertension in Pregnancy: Which Oral Medication is Optimal When IV Access is Limited?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site